drugset / Trial / NCT02369172

Drug-Drug Interaction Study: ASP2151 and Bupropion

NCT02369172

Phase 1 Completed 24 enrolled Maruho Europe Limited
Non-randomizedSingle-groupOpen-labelOther

Summary

CYP2B6 is involved in the metabolism of many drugs. So, it is important to assess in vivo the effect of ASP2151 on that enzyme to determine any possible drug interactions. The aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP2B6 probe substrate bupropion.

Timeline

Start
2015-02
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amenamevir Small molecule 400 mg Oral
Subject Bupropion Small molecule 150 mg

Indications

No indication recorded.